The Pharmaceutical Industry is changing. While the North American and European markets have seen growth in this industry slow, facilities close and jobs being lost as the big pharma companies attempt to adjust to changing economic conditions, increasing generic competition as patents expire and dwindling drug pipelines, the Asia-Pacific region has seen a rapid shift and subsequent growth which shows no signs of slowing now. The “Emerging Markets” are benefitting from a combination of factors including, changing economic conditions, a highly educated and skilled potential workforce and lower overall costs of production, which have encouraged the major Pharma/Biopharma companies to look east and make continuing substantial investments in R&D and Manufacturing operations in the region.

To ensure that this fast growing market is supplied with the highest quality, most cutting edge information regarding all of the technological and scientific advancements which will affect the current and future developments of Biopharmaceutical and Pharmaceutical therapeutics in the region, 888 Publishing ltd and its team with a combined experience of over 25 years of publishing the highest quality life science journals in the industry, is proud to present BioPharma Asia the premier source for unbiased, cutting edge editorial written the leading figures currently working in the global Pharma/Biopharma industry.

BioPharma Asia aims to keep its readers abreast of all developments in the areas of Drug Development, Drug Delivery, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality articles, written by the most respected authors, associated with only end-user companies. This ensures that the information will always be guaranteed to remain timely, informative and above all totally unbiased.